🇺🇸 Klimadynon in United States

16 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 16

Most-reported reactions

1. Fatigue — 3 reports (18.75%)
2. Akathisia — 2 reports (12.5%)
3. Dyskinesia — 2 reports (12.5%)
4. Listless — 2 reports (12.5%)
5. Tremor — 2 reports (12.5%)
6. Adrenal Adenoma — 1 report (6.25%)
7. Alopecia Areata — 1 report (6.25%)
8. Angina Pectoris — 1 report (6.25%)
9. Asthenia — 1 report (6.25%)
10. Blood Pressure Systolic Increased — 1 report (6.25%)

Source database →

Frequently asked questions

Is Klimadynon approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Klimadynon in United States?

Scientific Research Institute of Public Health, Russian Federation is the originator. The local marketing authorisation holder may differ — check the official source linked above.